Johnson & Johnson (JNJ) Shares Bought by Fisher Asset Management LLC
Fisher Asset Management LLC grew its holdings in Johnson & Johnson (NYSE:JNJ) by 2.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 11,797,674 shares of the company’s stock after purchasing an additional 298,259 shares during the quarter. Johnson & Johnson accounts for about 2.2% of Fisher Asset Management LLC’s holdings, making the stock its 7th biggest holding. Fisher Asset Management LLC owned about 0.44% of Johnson & Johnson worth $1,533,816,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also bought and sold shares of the company. Harding Loevner LP acquired a new stake in Johnson & Johnson in the second quarter valued at approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its holdings in Johnson & Johnson by 29.9% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after acquiring an additional 200 shares in the last quarter. Lenox Wealth Advisors Inc. raised its holdings in Johnson & Johnson by 0.6% in the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after acquiring an additional 5 shares in the last quarter. Mountain Capital Investment Advisors Inc acquired a new stake in Johnson & Johnson in the second quarter valued at approximately $124,000. Finally, Shine Investment Advisory Services Inc. acquired a new stake in Johnson & Johnson in the second quarter valued at approximately $177,000. 65.70% of the stock is owned by institutional investors and hedge funds.
Shares of Johnson & Johnson (NYSE JNJ) opened at $140.12 on Friday. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a 1-year low of $110.76 and a 1-year high of $144.35. The firm has a market cap of $376,440.00, a P/E ratio of 24.33, a price-to-earnings-growth ratio of 2.87 and a beta of 0.80.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The company had revenue of $19.65 billion for the quarter, compared to analysts’ expectations of $19.29 billion. During the same quarter last year, the company earned $1.68 earnings per share. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. sell-side analysts expect that Johnson & Johnson will post 7.28 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th were issued a dividend of $0.84 per share. The ex-dividend date of this dividend was Monday, November 27th. This represents a $3.36 dividend on an annualized basis and a yield of 2.40%. Johnson & Johnson’s payout ratio is currently 58.33%.
Several brokerages recently weighed in on JNJ. Citigroup raised their target price on shares of Johnson & Johnson from $140.00 to $149.00 and gave the company a “buy” rating in a report on Monday, October 23rd. Vetr raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 target price on the stock in a report on Monday, October 30th. Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th. BMO Capital Markets raised their target price on shares of Johnson & Johnson to $161.00 and gave the company an “outperform” rating in a report on Tuesday, December 12th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $165.00 target price (up previously from $150.00) on shares of Johnson & Johnson in a report on Wednesday, October 18th. Four research analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have given a buy rating to the company. Johnson & Johnson presently has an average rating of “Hold” and a consensus target price of $145.47.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.